Get the Stockscreener App
239.78
1.12%
2.65
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $239.78, with a volume of 702.85K.
It is up +1.12% in the last 24 hours and down -1.17% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$237.13
Open:
$237.99
24h Volume:
702.85K
Relative Volume:
0.84
Market Cap:
$35.23B
Revenue:
$4.81B
Net Income/Loss:
$1.11B
P/E Ratio:
31.76
EPS:
7.55
Net Cash Flow:
$1.35B
1W Performance:
+2.55%
1M Performance:
-1.17%
6M Performance:
+16.43%
1Y Performance:
+40.46%
1-Day Range:
$235.88
$240.37
1-Week Range:
$227.26
$240.60
52-Week Range:
$170.39
$260.49
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
239.78 | 35.23B | 4.81B | 1.11B | 1.35B | 7.55 |
|
ISRG
Intuitive Surgical Inc
|
592.64 | 211.09B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
237.38 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.37 | 41.73B | 9.76B | 1.16B | 665.00M | 2.34 |
|
WST
West Pharmaceutical Services Inc
|
336.34 | 24.40B | 2.88B | 499.60M | 321.60M | 6.74 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Assistive Technology Market Set to Witness Significant Growth by 2025-2032: Sunrise Medical LLC., Tobii AB, - EIN News
ResMed Gains 37.8% in a Year: What's Driving the Stock? - MSN
Integrated Investment Consultants LLC Invests $1.38 Million in ResMed Inc. (NYSE:RMD) - MarketBeat
Occidental Asset Management LLC Purchases Shares of 1,453 ResMed Inc. (NYSE:RMD) - MarketBeat
Goldman Sachs tips ResMed shares to rocket 30% to a record high - MSN
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Goldman Sachs starts coverage on ResMed with "buy" rating - MSN
The Goldman Sachs Group Begins Coverage on ResMed (NYSE:RMD) - MarketBeat
ASX Broker Moves: Upgrades for Baby Bunting, Resmed vs Downgrades for Computershare, Monadelphous, Beach Energy - MSN
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Peak Financial Advisors LLC Invests $2.97 Million in ResMed Inc. (NYSE:RMD) - MarketBeat
Board of the Pension Protection Fund Makes New $915,000 Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
The Zacks Analyst Blog Highlights Vertiv, Goldman Sachs, ResMed, Ralph Lauren and Amazon - Yahoo Finance
Czech National Bank Raises Stock Position in ResMed Inc. (NYSE:RMD) - Defense World
ResMed shares are up 42% in a year. This shows why they could still be great value - MSN
ResMed shares are in a two-month lull. Is this a chance to buy? - MSN
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Respiratory Devices Market Set to Witness Significant Growth by 2024-2031 | Medtronic, Hamilton Medical, - EIN News
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Zacks.com featured highlights Chipotle Mexican Grill, ResMed and ServiceNow - Yahoo Finance
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus.com
Is There An Opportunity With ResMed Inc.'s (NYSE:RMD) 31% Undervaluation? - Yahoo Finance
Piper Sandler Initiates Coverage of ResMed (RMD) with Neutral Recommendation - MSN
ResMed CFO Brett Sandercock sells shares worth $234,040 By Investing.com - Investing.com Australia
ResMed CFO Brett Sandercock sells shares worth $234,040 - Investing.com India
ResMed Inc. stock outperforms market despite losses on the day - MarketWatch
Piper Sandler Begins Coverage on ResMed (NYSE:RMD) - MarketBeat
Piper Sandler starts ResMed stock at Neutral, says execution rock solid By Investing.com - Investing.com South Africa
Piper Sandler starts ResMed stock at Neutral, says execution rock solid - Investing.com India
What 5 Analyst Ratings Have To Say About ResMed - Benzinga
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025 - GlobeNewswire
Sleep Study Equipment Market Seeking Excellent Growth | ResMed, - openPR
ResMed Inc. (NYSE:RMD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Resmed Inc Officer Plans Further Sale of Common Shares - TipRanks
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why - MSN
Here's Why ResMed (RMD) is a Strong Growth Stock - MSN
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Birch Capital Management LLC Raises Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Nordea Investment Management AB Acquires 215,561 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
ResMed Chairman Emeritus Disposes Shares in Planned Transaction - MSN
ResMed Inc. Reports Change in Beneficial Ownership - MSN
ResMed's Quarterly Earnings Preview: What You Need to Know - Nasdaq
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus.com
ResMed launches head strap for Apple's Vision Pro system - MSN
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):